Van beleggers
voor beleggers
desktop iconMarkt Monitor
  • Word abonnee
  • Inloggen

    Inloggen

    • Geen account? Registreren

    Wachtwoord vergeten?

Ontvang nu dagelijks onze kooptips!

word abonnee

Wat na ABLYNX welke aandeln kunnen veel groeien om welke redenen.

3 Posts
| Omlaag ↓
  1. [verwijderd] 1 februari 2018 11:34
    Merus, bispecifieke antibodies zijn de toekomst. bivoorbeeld: Basel, June 28, 2016 - Today Novartis announced that it has entered into a collaboration and licensing agreement with Xencor for the development of bispecific antibodies for treating cancer. The agreement is the latest in a series of acquisitions and strategic collaborations between Novartis and biotech companies that have helped bolster its deep and diverse immuno-oncology pipeline.

    Traditional monoclonal antibodies target and bind to a single antigen. Bispecific antibodies are engineered to recognize and target two different antigens, which makes them potentially more effective in targeting complex diseases. A T-cell engaging bispecific antibody is able to bind an antigen on a tumor cell with one arm and engage T-cells capable of their destruction with the other.
3 Posts
|Omhoog ↑

Meedoen aan de discussie?

Word nu gratis lid of log in met je emailadres en wachtwoord.

Direct naar Forum

Indices

AEX 910,17 +0,66%
EUR/USD 1,0765 -0,15%
FTSE 100 8.438,49 +0,68%
Germany40^ 18.761,00 +0,40%
Gold spot 2.360,55 +0,61%
NY-Nasdaq Composite 16.346,27 +0,27%

Stijgers

UCB
+3,28%
Ontex
+2,56%
Elia
+1,89%
Lotus ...
+1,75%
bpost
+1,61%

Dalers

Bekaert
-2,66%
Solvay
-2,30%
Deceun...
-1,96%
D'IETE...
-1,09%
SYENSQO
-1,09%

Lees verder op het IEX netwerk Let op: Artikelen linken naar andere sites

Gesponsorde links